0	0	1998-09-23	CD	O	O	B-Num
0	1	23	CD	O	O	B-Num
0	2	:	:	O	O	I-Num
0	3	25	CD	O	B-NP	I-Num
0	4	BAYER	NNP	O	I-NP	O
0	5	TO	TO	O	B-VP	O
0	6	PAY	VB	O	I-VP	O
0	7	$96.6	NN	O	B-NP	B-Money
0	8	MILLION	NNP	O	I-NP	B-Num
0	9	FOR	IN	O	B-PP	O
0	10	STAKE	NNP	O	B-NP	O
0	11	IN	IN	O	B-PP	O
0	12	MILLENNIUM	NNP	O	B-NP	O

1	0	Bayer	NNP	O	B-NP	B-Peop
1	1	A.G.	NNP	O	I-NP	I-Peop
1	2	COMMA	COMMA	O	O	I-Peop
1	3	the	DT	O	B-NP	I-Peop
1	4	German	JJ	O	I-NP	I-Peop
1	5	drug	NN	O	I-NP	I-Peop
1	6	and	CC	O	I-NP	I-Peop
1	7	chemical	NN	O	I-NP	I-Peop
1	8	company	NN	O	I-NP	I-Peop
1	9	COMMA	COMMA	O	O	I-Peop
1	10	said	VBD	O	B-VP	I-Peop
1	11	on	IN	O	B-PP	I-Peop
1	12	Wednesday	NNP	O	B-NP	I-Peop
1	13	that	IN	O	O	I-Peop
1	14	it	PRP	O	B-NP	I-Peop
1	15	would	MD	O	B-VP	I-Peop
1	16	pay	VB	O	I-VP	I-Peop
1	17	$96.6	NN	O	B-NP	I-Peop
1	18	million	CD	O	I-NP	I-Peop
1	19	to	TO	O	B-VP	I-Peop
1	20	buy	VB	O	I-VP	I-Peop
1	21	a	DT	O	B-NP	I-Peop
1	22	14	CD	O	I-NP	I-Peop
1	23	percent	NN	O	I-NP	I-Peop
1	24	equity	NN	O	I-NP	I-Peop
1	25	stake	NN	O	I-NP	I-Peop
1	26	in	IN	O	B-PP	I-Peop
1	27	Millennium	NNP	O	B-NP	I-Peop
1	28	Pharmaceuticals	NNP	O	I-NP	I-Peop
1	29	Inc.	NNP	O	I-NP	I-Peop
1	30	COMMA	COMMA	O	O	O
1	31	a	DT	O	B-NP	O
1	32	genomics	NNS	O	I-NP	B-Jour
1	33	company	NN	O	I-NP	B-OrgCorp
1	34	in	IN	O	B-PP	O
1	35	Cambridge	NNP	O	B-NP	B-Loc
1	36	COMMA	COMMA	O	O	O
1	37	Mass	NNP	O	B-NP	B-Loc
1	38	.	.	O	O	O

2	0	Bayer	NNP	O	B-NP	B-OrgCorp
2	1	will	MD	O	B-VP	O
2	2	also	RB	O	I-VP	O
2	3	pay	VB	O	I-VP	O
2	4	$33.4	NN	O	B-NP	B-Money
2	5	million	CD	O	I-NP	B-Num
2	6	in	IN	O	B-PP	O
2	7	licensing	NN	O	B-NP	O
2	8	fees	NNS	O	I-NP	O
2	9	COMMA	COMMA	O	O	O
2	10	and	CC	O	O	O
2	11	up	IN	O	O	O
2	12	to	TO	O	O	O
2	13	$335	NN	O	B-NP	B-Money
2	14	million	CD	O	I-NP	B-Num
2	15	in	IN	O	B-PP	O
2	16	research	NN	O	B-NP	O
2	17	and	CC	O	I-NP	O
2	18	development	NN	O	I-NP	O
2	19	financing	NN	O	I-NP	O
2	20	in	IN	O	B-PP	O
2	21	the	DT	O	B-NP	O
2	22	next	JJ	O	I-NP	O
2	23	five	CD	O	I-NP	B-Num
2	24	years	NNS	O	I-NP	B-Date
2	25	.	.	O	O	O

3	0	The	DT	O	B-NP	O
3	1	ultimate	JJ	O	I-NP	O
3	2	amount	NN	O	I-NP	O
3	3	of	IN	O	B-PP	O
3	4	the	DT	O	B-NP	O
3	5	financing	NN	O	I-NP	O
3	6	is	VBZ	O	B-VP	O
3	7	dependent	JJ	O	O	B-Medical
3	8	upon	IN	O	B-PP	O
3	9	Millennium	NNP	O	B-NP	B-Peop
3	10	's	POS	O	B-NP	O
3	11	identification	NN	O	I-NP	B-Medical
3	12	of	IN	O	B-PP	O
3	13	225	CD	O	B-NP	B-Num
3	14	targets	NNS	O	I-NP	O
3	15	for	IN	O	B-PP	O
3	16	new	JJ	O	B-NP	O
3	17	drugs	NNS	O	I-NP	O
3	18	for	IN	O	B-PP	O
3	19	cardiovascular	JJ	O	B-NP	B-Medical
3	20	disease	NN	O	I-NP	B-Medical
3	21	COMMA	COMMA	O	O	O
3	22	cancer	NN	O	B-NP	B-Medical
3	23	COMMA	COMMA	O	O	O
3	24	osteoporosis	NN	O	B-NP	B-Medical
3	25	COMMA	COMMA	O	I-NP	O
3	26	pain	NN	O	I-NP	O
3	27	COMMA	COMMA	O	O	O
3	28	liver	NN	O	B-NP	O
3	29	fibrosis	NN	O	I-NP	B-Medical
3	30	COMMA	COMMA	O	O	O
3	31	hematology	NN	O	B-NP	O
3	32	and	CC	O	I-NP	O
3	33	viral	JJ	O	I-NP	B-Medical
3	34	infections	NNS	O	I-NP	O
3	35	.	.	O	O	O

4	0	Analysts	NNS	O	B-NP	B-Peop
4	1	said	VBD	O	B-VP	O
4	2	the	DT	O	B-NP	O
4	3	deal	NN	O	I-NP	O
4	4	was	VBD	O	B-VP	O
4	5	one	CD	O	B-NP	B-Num
4	6	of	IN	O	B-PP	O
4	7	the	DT	O	B-NP	O
4	8	richest	JJS	O	I-NP	O
4	9	ever	RB	O	O	O
4	10	between	IN	O	B-PP	O
4	11	a	DT	O	B-NP	O
4	12	large	JJ	O	I-NP	O
4	13	pharmaceuticals	NNS	O	I-NP	O
4	14	concern	NN	O	I-NP	O
4	15	and	CC	O	O	O
4	16	a	DT	O	B-NP	O
4	17	biotechnology	NN	O	I-NP	O
4	18	company	NN	O	I-NP	B-OrgCorp
4	19	COMMA	COMMA	O	O	O
4	20	and	CC	O	O	O
4	21	a	DT	O	B-NP	O
4	22	validation	NN	O	I-NP	O
4	23	of	IN	O	B-PP	O
4	24	Millennium	NNP	O	B-NP	B-Peop
4	25	's	POS	O	B-NP	O
4	26	science	NN	O	I-NP	O
4	27	and	CC	O	I-NP	O
4	28	strategy	NN	O	I-NP	O
4	29	.	.	O	O	O

5	0	Although	IN	O	O	O
5	1	Millennium	NNP	O	B-NP	B-Peop
5	2	has	VBZ	O	B-VP	O
5	3	had	VBD	O	I-VP	O
5	4	a	DT	O	B-NP	O
5	5	lower	JJR	O	I-NP	O
5	6	profile	NN	O	I-NP	O
5	7	than	IN	O	B-PP	O
5	8	competitors	NNS	O	B-NP	O
5	9	like	IN	O	B-PP	O
5	10	Human	NNP	O	B-NP	B-Animal
5	11	Genome	NNP	O	I-NP	B-Jour
5	12	Sciences	NNPS	O	I-NP	O
5	13	Inc.	NNP	O	I-NP	O
5	14	or	CC	O	O	O
5	15	Incyte	NNP	O	B-NP	O
5	16	Pharmaceuticals	NNP	O	I-NP	O
5	17	Inc.	NNP	O	I-NP	O
5	18	COMMA	COMMA	O	O	O
5	19	it	PRP	O	B-NP	O
5	20	currently	RB	O	O	O
5	21	has	VBZ	O	B-VP	O
5	22	more	JJR	O	B-NP	O
5	23	than	IN	O	B-PP	O
5	24	$1	NN	O	B-NP	B-Money
5	25	billion	CD	O	I-NP	B-Num
5	26	in	IN	O	B-PP	O
5	27	potential	JJ	O	B-NP	O
5	28	pharmaceutical	JJ	O	I-NP	B-Medical
5	29	partnership	NN	O	I-NP	O
5	30	financing	NN	O	I-NP	O
5	31	.	.	O	O	O

6	0	``	``	O	O	O
6	1	For	IN	O	B-PP	O
6	2	Millennium	NNP	O	B-NP	O
6	3	it	PRP	O	B-NP	O
6	4	is	VBZ	O	B-VP	O
6	5	a	DT	O	B-NP	O
6	6	critical	JJ	O	I-NP	O
6	7	deal	NN	O	I-NP	O
6	8	COMMA	COMMA	O	O	O
6	9	both	DT	O	O	O
6	10	in	IN	O	B-PP	O
6	11	terms	NNS	O	B-NP	O
6	12	of	IN	O	B-PP	O
6	13	alleviating	VBG	O	B-VP	O
6	14	their	PP$	O	B-NP	O
6	15	short-term	JJ	O	I-NP	O
6	16	cash	NN	O	I-NP	O
6	17	flow	NN	O	I-NP	O
6	18	problems	NNS	O	I-NP	O
6	19	COMMA	COMMA	O	O	O
6	20	and	CC	O	O	O
6	21	allowing	VBG	O	B-VP	O
6	22	them	PRP	O	B-NP	O
6	23	to	TO	O	B-VP	O
6	24	increase	VB	O	I-VP	O
6	25	productivity	NN	O	B-NP	O
6	26	across	IN	O	B-PP	O
6	27	the	DT	O	B-NP	O
6	28	board	NN	O	I-NP	O
6	29	for	IN	O	B-PP	O
6	30	their	PP$	O	B-NP	O
6	31	in-house	JJ	O	I-NP	O
6	32	research	NN	O	I-NP	O
6	33	and	CC	O	I-NP	O
6	34	developmentCOMMA	NN	O	I-NP	O
6	35	''	''	O	O	O
6	36	said	VBD	O	B-VP	O
6	37	Akhtar	NNP	O	B-NP	B-Peop
6	38	Samad	NNP	O	I-NP	I-Peop
6	39	COMMA	COMMA	O	O	O
6	40	an	DT	O	B-NP	O
6	41	analyst	NN	O	I-NP	B-ProfTitle
6	42	with	IN	O	B-PP	O
6	43	Mehta	NNP	O	B-NP	O
6	44	Partners	NNPS	O	I-NP	O
6	45	.	.	O	O	O

7	0	Noting	VBG	O	B-VP	O
7	1	that	IN	O	O	O
7	2	Millennium	NNP	O	B-NP	B-Peop
7	3	had	VBD	O	B-VP	O
7	4	previously	RB	O	I-VP	O
7	5	entered	VBN	O	I-VP	O
7	6	partnerships	NNS	O	B-NP	O
7	7	with	IN	O	B-PP	O
7	8	Roche	NNP	O	B-NP	B-Peop
7	9	Holding	NNP	O	I-NP	B-Peop
7	10	A.G.	NNP	O	I-NP	I-Peop
7	11	and	CC	O	O	O
7	12	Monsanto	NNP	O	B-NP	B-OrgCorp
7	13	COMMA	COMMA	O	O	O
7	14	he	PRP	O	B-NP	O
7	15	added	VBD	O	B-VP	O
7	16	COMMA	COMMA	O	O	O
7	17	``	``	O	O	O
7	18	the	DT	O	B-NP	O
7	19	potential	JJ	O	I-NP	O
7	20	downstream	JJ	O	I-NP	O
7	21	concern	NN	O	I-NP	O
7	22	is	VBZ	O	B-VP	O
7	23	that	IN	O	O	O
7	24	their	PP$	O	O	O
7	25	different	JJ	O	B-NP	O
7	26	corporate	JJ	O	I-NP	O
7	27	partners	NNS	O	I-NP	O
7	28	may	MD	O	B-VP	O
7	29	wind	VB	O	I-VP	O
7	30	up	IN	O	O	O
7	31	being	VBG	O	B-VP	O
7	32	direct	JJ	O	B-NP	O
7	33	competitors	NNS	O	I-NP	O
7	34	.	.	O	O	O
7	35	''	''	O	O	O

8	0	Millennium	NN	O	B-NP	O
8	1	shares	NNS	O	I-NP	O
8	2	rose	VBD	O	B-VP	O
8	3	$1.4375	NN	O	B-NP	B-Money
8	4	on	IN	O	B-PP	O
8	5	Wednesday	NNP	O	B-NP	B-Date
8	6	COMMA	COMMA	O	O	O
8	7	to	TO	O	B-PP	O
8	8	$18.6875	NN	O	B-NP	B-Money
8	9	COMMA	COMMA	O	O	O
8	10	in	IN	O	B-PP	O
8	11	Nasdaq	NNP	O	B-NP	B-Loc
8	12	trading	NN	O	I-NP	O
8	13	.	.	O	O	O

9	0	The	DT	O	B-NP	O
9	1	deal	NN	O	I-NP	O
9	2	gave	VBD	O	B-VP	O
9	3	Bayer	NNP	O	B-NP	B-OrgCorp
9	4	access	NN	O	I-NP	O
9	5	to	TO	O	B-PP	O
9	6	the	DT	O	B-NP	O
9	7	leading	VBG	O	I-NP	O
9	8	edge	NN	O	I-NP	O
9	9	of	IN	O	B-PP	O
9	10	drug	NN	O	B-NP	B-Medical
9	11	discovery	NN	O	I-NP	O
9	12	technology	NN	O	I-NP	O
9	13	.	.	O	O	O

10	0	Genomics	NNS	O	B-NP	B-Jour
10	1	COMMA	COMMA	O	O	O
10	2	the	DT	O	B-NP	O
10	3	effort	NN	O	I-NP	O
10	4	to	TO	O	B-VP	O
10	5	spell	VB	O	I-VP	O
10	6	out	IN	O	O	O
10	7	all	DT	O	B-NP	O
10	8	of	IN	O	B-PP	O
10	9	the	DT	O	B-NP	O
10	10	body	NN	O	I-NP	O
10	11	's	POS	O	B-NP	O
10	12	genes	NNS	O	I-NP	O
10	13	and	CC	O	O	O
10	14	seek	VBP	O	B-VP	O
10	15	correlations	NNS	O	B-NP	O
10	16	between	IN	O	B-PP	O
10	17	genetic	JJ	O	B-NP	B-Medical
10	18	mutations	NNS	O	I-NP	O
10	19	and	CC	O	B-NP	O
10	20	disease	NN	O	I-NP	B-Medical
10	21	COMMA	COMMA	O	O	O
10	22	remains	VBZ	O	B-VP	O
10	23	a	DT	O	B-NP	O
10	24	controversial	JJ	O	I-NP	O
10	25	subject	NN	O	I-NP	O
10	26	in	IN	O	B-PP	O
10	27	Germany	NNP	O	B-NP	B-LocCoun
10	28	.	.	O	O	O

11	0	``	``	O	O	O
11	1	It	PRP	O	B-NP	O
11	2	is	VBZ	O	B-VP	O
11	3	now	RB	O	O	O
11	4	possible	JJ	O	O	O
11	5	to	TO	O	B-VP	O
11	6	employ	VB	O	I-VP	O
11	7	genomic	JJ	O	B-NP	O
11	8	research	NN	O	I-NP	O
11	9	for	IN	O	B-PP	O
11	10	the	DT	O	B-NP	O
11	11	development	NN	O	I-NP	O
11	12	of	IN	O	B-PP	O
11	13	drugs	NNS	O	B-NP	O
11	14	on	IN	O	B-PP	O
11	15	an	DT	O	B-NP	O
11	16	industrial	JJ	O	I-NP	O
11	17	scaleCOMMA	NN	O	I-NP	O
11	18	''	''	O	O	O
11	19	Dr.	NNP	O	B-NP	B-ProfTitle
11	20	Wolfgang	NNP	O	I-NP	B-Peop
11	21	Hartwig	NNP	O	I-NP	I-Peop
11	22	COMMA	COMMA	O	O	O
11	23	Bayer	NNP	O	B-NP	B-OrgCorp
11	24	's	POS	O	B-NP	O
11	25	head	NN	O	I-NP	O
11	26	of	IN	O	B-PP	O
11	27	pharmaceuticals	NNS	O	B-NP	O
11	28	research	NN	O	I-NP	O
11	29	COMMA	COMMA	O	O	O
11	30	said	VBD	O	B-VP	O
11	31	in	IN	O	B-PP	O
11	32	a	DT	O	B-NP	O
11	33	statement	NN	O	I-NP	O
11	34	.	.	O	O	O

12	0	``	``	O	O	O
12	1	Bayer	NNP	O	B-NP	B-Peop
12	2	is	VBZ	O	B-VP	O
12	3	saying	VBG	O	I-VP	O
12	4	that	IN	O	O	O
12	5	they	PRP	O	B-NP	O
12	6	believe	VBP	O	B-VP	O
12	7	Millennium	NNP	O	B-NP	O
12	8	can	MD	O	B-VP	O
12	9	act	VB	O	I-VP	O
12	10	as	IN	O	B-PP	O
12	11	a	DT	O	B-NP	O
12	12	front	NN	O	I-NP	O
12	13	end	NN	O	I-NP	O
12	14	COMMA	COMMA	O	O	O
12	15	as	IN	O	O	O
12	16	the	DT	O	B-NP	O
12	17	discovery	NN	O	I-NP	O
12	18	organization	NN	O	I-NP	O
12	19	that	WDT	O	B-NP	O
12	20	can	MD	O	B-VP	O
12	21	substitute	VB	O	I-VP	O
12	22	for	IN	O	B-PP	O
12	23	an	DT	O	B-NP	O
12	24	internal	JJ	O	I-NP	O
12	25	programCOMMA	NN	O	I-NP	O
12	26	''	''	O	O	O
12	27	said	VBD	O	B-VP	O
12	28	Michael	NNP	O	B-NP	B-Peop
12	29	King	NNP	O	I-NP	I-Peop
12	30	COMMA	COMMA	O	O	O
12	31	an	DT	O	B-NP	O
12	32	analyst	NN	O	I-NP	B-ProfTitle
12	33	with	IN	O	B-PP	O
12	34	BancBoston	NNP	O	B-NP	O
12	35	Robertson	NNP	O	I-NP	B-Peop
12	36	Stephens	NNP	O	I-NP	I-Peop
12	37	Inc	NNP	O	I-NP	I-Peop
12	38	.	.	O	O	O

13	0	``	``	O	O	O
13	1	Millennium	NNP	O	B-NP	B-Peop
13	2	appears	VBZ	O	B-VP	O
13	3	to	TO	O	I-VP	O
13	4	be	VB	O	I-VP	O
13	5	very	RB	O	O	O
13	6	good	JJ	O	O	O
13	7	at	IN	O	B-PP	O
13	8	coming	VBG	O	B-VP	O
13	9	up	IN	O	O	O
13	10	with	IN	O	B-PP	O
13	11	a	DT	O	B-NP	O
13	12	lot	NN	O	I-NP	O
13	13	of	IN	O	B-PP	O
13	14	targets	NNS	O	B-NP	O
13	15	in	IN	O	B-PP	O
13	16	a	DT	O	B-NP	O
13	17	rapid	JJ	O	I-NP	O
13	18	fashionCOMMA	NN	O	I-NP	O
13	19	''	''	O	O	O
13	20	he	PRP	O	B-NP	O
13	21	said	VBD	O	B-VP	O
13	22	.	.	O	O	O

14	0	For	IN	O	B-PP	O
14	1	Millennium	NNP	O	B-NP	O
14	2	COMMA	COMMA	O	O	O
14	3	Bayer	NNP	O	B-NP	B-OrgCorp
14	4	's	POS	O	B-NP	O
14	5	financing	NN	O	I-NP	O
14	6	``	``	O	O	O
14	7	will	MD	O	B-VP	O
14	8	give	VB	O	I-VP	O
14	9	us	PRP	O	B-NP	O
14	10	some	DT	O	B-NP	O
14	11	really	RB	O	I-NP	O
14	12	strong	JJ	O	I-NP	O
14	13	discovery	NN	O	I-NP	O
14	14	and	CC	O	I-NP	O
14	15	development	NN	O	I-NP	O
14	16	capabilityCOMMA	NN	O	I-NP	O
14	17	''	''	O	O	O
14	18	Mark	NNP	O	B-NP	B-Peop
14	19	Levin	NNP	O	I-NP	I-Peop
14	20	COMMA	COMMA	O	O	O
14	21	Millennium	NNP	O	B-NP	B-Peop
14	22	's	POS	O	B-NP	O
14	23	president	NN	O	I-NP	B-ProfTitle
14	24	and	CC	O	I-NP	O
14	25	chief	NN	O	I-NP	B-ProfTitle
14	26	executive	NN	O	I-NP	B-ProfTitle
14	27	COMMA	COMMA	O	O	O
14	28	said	VBD	O	B-VP	O
14	29	in	IN	O	B-PP	O
14	30	a	DT	O	B-NP	O
14	31	telephone	NN	O	I-NP	O
14	32	interview	NN	O	I-NP	O
14	33	.	.	O	O	O

15	0	``	``	O	O	O
15	1	Out	IN	O	B-PP	O
15	2	of	IN	O	B-PP	O
15	3	the	DT	O	B-NP	O
15	4	225	CD	O	I-NP	B-Num
15	5	targets	NNS	O	I-NP	O
15	6	COMMA	COMMA	O	O	O
15	7	Millennium	NNP	O	B-NP	B-Peop
15	8	will	MD	O	B-VP	O
15	9	actually	RB	O	I-VP	O
15	10	get	VB	O	I-VP	O
15	11	90	CD	O	B-NP	B-NumPercent
15	12	percent	NN	O	I-NP	I-NumPercent
15	13	of	IN	O	B-PP	O
15	14	them	PRP	O	B-NP	O
15	15	backCOMMA	NN	O	B-NP	O
15	16	''	''	O	O	O
15	17	after	IN	O	B-PP	O
15	18	Bayer	NNP	O	B-NP	B-Peop
15	19	's	POS	O	B-NP	O
15	20	review	NN	O	I-NP	O
15	21	COMMA	COMMA	O	O	O
15	22	he	PRP	O	B-NP	O
15	23	said	VBD	O	B-VP	O
15	24	.	.	O	O	O

16	0	``	``	O	O	O
16	1	On	IN	O	B-PP	O
16	2	top	JJ	O	B-NP	O
16	3	of	IN	O	B-PP	O
16	4	that	DT	O	B-NP	O
16	5	COMMA	COMMA	O	O	O
16	6	we	PRP	O	B-NP	O
16	7	retain	VBP	O	B-VP	O
16	8	all	DT	O	B-NP	O
16	9	biotherapeutic	JJ	O	I-NP	O
16	10	and	CC	O	I-NP	O
16	11	agricultural	JJ	O	I-NP	O
16	12	rightsCOMMA	NN	O	I-NP	O
16	13	''	''	O	O	O
16	14	he	PRP	O	B-NP	O
16	15	said	VBD	O	B-VP	O
16	16	.	.	O	O	O

17	0	Biotherapeutics	NNP	O	B-NP	O
17	1	includes	VBZ	O	B-VP	O
17	2	proteins	NNS	O	B-NP	O
17	3	and	CC	O	I-NP	O
17	4	antibodies	NNS	O	I-NP	O
17	5	COMMA	COMMA	O	O	O
17	6	but	CC	O	O	O
17	7	not	RB	O	O	O
17	8	traditional	JJ	O	B-NP	O
17	9	small	JJ	O	I-NP	O
17	10	molecule	NN	O	I-NP	O
17	11	drugs	NNS	O	I-NP	O
17	12	.	.	O	O	O

18	0	Levin	NNP	O	B-NP	B-Peop
18	1	said	VBD	O	B-VP	O
18	2	the	DT	O	B-NP	O
18	3	deal	NN	O	I-NP	O
18	4	means	VBZ	O	B-VP	O
18	5	Millennium	NNP	O	B-NP	B-Peop
18	6	will	MD	O	B-VP	O
18	7	be	VB	O	I-VP	O
18	8	profitable	JJ	O	O	O
18	9	this	DT	O	B-NP	O
18	10	year	NN	O	I-NP	O
18	11	.	.	O	O	O

19	0	Analysts	NNS	O	B-NP	B-ProfTitle
19	1	had	VBD	O	B-VP	O
19	2	expected	VBN	O	I-VP	O
19	3	the	DT	O	B-NP	O
19	4	company	NN	O	I-NP	B-OrgCorp
19	5	to	TO	O	B-VP	O
19	6	lose	VB	O	I-VP	O
19	7	21	CD	O	B-NP	B-Num
19	8	cents	NNS	O	I-NP	O
19	9	a	DT	O	B-NP	O
19	10	share	NN	O	I-NP	O
19	11	for	IN	O	B-PP	O
19	12	1998	CD	O	B-NP	B-Date
19	13	COMMA	COMMA	O	O	O
19	14	according	VBG	O	B-PP	O
19	15	to	TO	O	B-PP	O
19	16	First	RB	O	B-NP	B-Num
19	17	Call	NNP	O	I-NP	O
19	18	.	.	O	O	O
